Coding and Reimbursement Updates

This Month’s E-Reiumbursement Newsletter from Bobbi Buell for March 31, 2026

Read More

Corporate Member News

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

Read More

Pfizer Oncology is pleased to announce that the FDA has updated the Prescribing Information for BRAFTOVI® (encorafenib) on February 24, 2026 to include new data with an expanded indication.

Read More